The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery
The screening of potential therapeutic compounds using phenotypic drug discovery (PDD) is being embraced once again by researchers and pharmaceutical companies as an approach to enhance the development of new effective therapeutics. Before the genomics and molecular biology era and the consecutive e...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00894/full |
| _version_ | 1831738200349999104 |
|---|---|
| author | Natalia V. Segatto Mariana H. Remião Kyle M. Schachtschneider Fabiana K. Seixas Lawrence B. Schook Lawrence B. Schook Tiago Collares |
| author_facet | Natalia V. Segatto Mariana H. Remião Kyle M. Schachtschneider Fabiana K. Seixas Lawrence B. Schook Lawrence B. Schook Tiago Collares |
| author_sort | Natalia V. Segatto |
| collection | DOAJ |
| description | The screening of potential therapeutic compounds using phenotypic drug discovery (PDD) is being embraced once again by researchers and pharmaceutical companies as an approach to enhance the development of new effective therapeutics. Before the genomics and molecular biology era and the consecutive emergence of targeted-drug discovery approaches, PDD was the most common platform used for drug discovery. PDD, also known as phenotypic screening, consists of screening potential compounds in either in vitro cellular or in vivo animal models to identify compounds resulting in a desirable phenotypic change. Using this approach, the biological targets of the compounds are not taken into consideration. Suitable animal models are crucial for the continued validation and discovery of new drugs, as compounds displaying promising results in phenotypic in vitro cell-based and in vivo small animal model screenings often fail in clinical trials. Indeed, this is mainly a result of differential anatomy, physiology, metabolism, immunology, and genetics between humans and currently used pre-clinical small animal models. In contrast, pigs are more predictive of therapeutic treatment outcomes in humans than rodents. In addition, pigs provide an ideal platform to study cancer due to their similarities with humans at the anatomical, physiological, metabolic, and genetic levels. Here we provide a mini-review on the reemergence of PDD in drug development, highlighting the potential of porcine cancer models for improving pre-clinical drug discovery and testing. We also present precision medicine based genetically defined swine cancer models developed to date and their potential as biomedical models. |
| first_indexed | 2024-12-21T13:17:29Z |
| format | Article |
| id | doaj.art-a3636bfd4b74491fa163b67f5a4a0577 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-21T13:17:29Z |
| publishDate | 2017-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-a3636bfd4b74491fa163b67f5a4a05772022-12-21T19:02:41ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122017-12-01810.3389/fphar.2017.00894314927The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug DiscoveryNatalia V. Segatto0Mariana H. Remião1Kyle M. Schachtschneider2Fabiana K. Seixas3Lawrence B. Schook4Lawrence B. Schook5Tiago Collares6Biotechnology Graduate Program, Molecular and Cellular Oncology Research Group, Laboratory of Cancer Biotechnology, Technology Development Center, Federal University of Pelotas, Pelotas, BrazilBiotechnology Graduate Program, Molecular and Cellular Oncology Research Group, Laboratory of Cancer Biotechnology, Technology Development Center, Federal University of Pelotas, Pelotas, BrazilDepartment of Radiology, University of Illinois at Chicago, Chicago, IL, United StatesBiotechnology Graduate Program, Molecular and Cellular Oncology Research Group, Laboratory of Cancer Biotechnology, Technology Development Center, Federal University of Pelotas, Pelotas, BrazilDepartment of Radiology, University of Illinois at Chicago, Chicago, IL, United StatesDepartment of Animal Sciences, University of Illinois at Urbana–Champaign, Champaign, IL, United StatesBiotechnology Graduate Program, Molecular and Cellular Oncology Research Group, Laboratory of Cancer Biotechnology, Technology Development Center, Federal University of Pelotas, Pelotas, BrazilThe screening of potential therapeutic compounds using phenotypic drug discovery (PDD) is being embraced once again by researchers and pharmaceutical companies as an approach to enhance the development of new effective therapeutics. Before the genomics and molecular biology era and the consecutive emergence of targeted-drug discovery approaches, PDD was the most common platform used for drug discovery. PDD, also known as phenotypic screening, consists of screening potential compounds in either in vitro cellular or in vivo animal models to identify compounds resulting in a desirable phenotypic change. Using this approach, the biological targets of the compounds are not taken into consideration. Suitable animal models are crucial for the continued validation and discovery of new drugs, as compounds displaying promising results in phenotypic in vitro cell-based and in vivo small animal model screenings often fail in clinical trials. Indeed, this is mainly a result of differential anatomy, physiology, metabolism, immunology, and genetics between humans and currently used pre-clinical small animal models. In contrast, pigs are more predictive of therapeutic treatment outcomes in humans than rodents. In addition, pigs provide an ideal platform to study cancer due to their similarities with humans at the anatomical, physiological, metabolic, and genetic levels. Here we provide a mini-review on the reemergence of PDD in drug development, highlighting the potential of porcine cancer models for improving pre-clinical drug discovery and testing. We also present precision medicine based genetically defined swine cancer models developed to date and their potential as biomedical models.http://journal.frontiersin.org/article/10.3389/fphar.2017.00894/fullPDDanimal modelswineOncopig cancer modelcancer |
| spellingShingle | Natalia V. Segatto Mariana H. Remião Kyle M. Schachtschneider Fabiana K. Seixas Lawrence B. Schook Lawrence B. Schook Tiago Collares The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery Frontiers in Pharmacology PDD animal model swine Oncopig cancer model cancer |
| title | The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery |
| title_full | The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery |
| title_fullStr | The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery |
| title_full_unstemmed | The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery |
| title_short | The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery |
| title_sort | oncopig cancer model as a complementary tool for phenotypic drug discovery |
| topic | PDD animal model swine Oncopig cancer model cancer |
| url | http://journal.frontiersin.org/article/10.3389/fphar.2017.00894/full |
| work_keys_str_mv | AT nataliavsegatto theoncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery AT marianahremiao theoncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery AT kylemschachtschneider theoncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery AT fabianakseixas theoncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery AT lawrencebschook theoncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery AT lawrencebschook theoncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery AT tiagocollares theoncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery AT nataliavsegatto oncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery AT marianahremiao oncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery AT kylemschachtschneider oncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery AT fabianakseixas oncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery AT lawrencebschook oncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery AT lawrencebschook oncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery AT tiagocollares oncopigcancermodelasacomplementarytoolforphenotypicdrugdiscovery |